Bartira Rossi Bergmann

Instituição:

Universidade Federal do Rio de Janeiro

Centro:

Centro de Ciências da Saúde

Unidade:

Instituto de Biofísica Carlos Chagas Filho

Departamento:

Programa de Imunobiologia/Biof

ORCID:

não disponível no Lattes


Formação:

  • University of Toronto

    | Pós-Doutorado | 1994 - 1994

  • Brunel University London

    PhD in Biological Sciences | Doutorado | 1983 - 1987

  • London School of Hygiene and Tropical Medicine - University of London

    MSc in Medical Parasitology | Mestrado | 1981 - 1982

  • Universidade de São Paulo

    Ciências Biomédicas | Graduação | 1977 - 1980
Laboratórios:
Nuvens de Palavras:
Artigos:

(91.06% artigos com DOI)

Titulo DOI Ano
INTRANASAL DELIVERY OF LaAg VACCINE IMPROVES IMMUNITY OF AGED MICE AGAINST VISCERAL LEISHMANIASIS 10.1016/j.actatropica.2024.107125 2024
In Vivo Safety and Efficacy of Chalcone-Loaded Microparticles with Modified Polymeric Matrix against Cutaneous Leishmaniasis 10.3390/pharmaceutics15010051 2023
Cysteinyl-leukotrienes promote cutaneous Leishmaniasis control 10.3389/fcimb.2023.1192800 2023
Crosslinked chitosan microparticles as a safe and efficient DNA carrier for intranasal vaccination against cutaneous leishmaniasis 10.1016/j.jvacx.2023.100403 2023
Synthesis and evaluation of hybrid sulfonamide-chalcones with potential antileishmanial activity 10.1002/ardp.202300440 2023
Targeting chalcone binding sites in living Leishmania using a reversible fluorogenic benzochalcone probe 10.1016/j.biopha.2022.112784 2022
Eugenol derivatives with 1,2,3-triazole moieties: Oral treatment of cutaneous leishmaniasis and a quantitative structure-activity relationship model for their leishmanicidal activity 10.1016/j.exppara.2022.108269 2022
Development of Immunological Assays Based on Leishmania donovani Antigen for Diagnosis of Canine Visceral Leishmaniasis and Their Multicenter Evaluation in Brazil and Italy 10.3389/fcimb.2022.914477 2022
Intradermal Immunization of SARS-CoV-2 Original Strain Trimeric Spike Protein Associated to CpG and AddaS03 Adjuvants, but Not MPL, Provide Strong Humoral and Cellular Response in Mice. 10.3390/vaccines10081305 2022
Immunogenicity of SARS-CoV-2 Trimeric Spike Protein Associated to Poly(I:C) Plus Alum 10.3389/fimmu.2022.884760 2022
Intranasal immunization with chitosan microparticles enhances LACK-DNA vaccine protection and induces specific long-lasting immunity against visceral leishmaniasis 10.1016/j.micinf.2021.104884 2022
Antileishmanial Chemotherapy through Clemastine Fumarate Mediated Inhibition of the Leishmania Inositol Phosphorylceramide Synthase 10.1021/acsinfecdis.0c00546 2021
MPLA and AddaVax® Adjuvants Fail to Promote Intramuscular LaAg Vaccine Protectiveness against Experimental Cutaneous Leishmaniasis 10.3390/microorganisms9061272 2021
Leishmanicidal and cytotoxic activities and 4D-QSAR of 2-arylidene indan-1,3-diones 10.1002/ardp.202100081 2021
Chalcones identify cTXNPx as a potential antileishmanial drug target 10.1371/journal.pntd.0009951 2021
Leishmanicidal activity of Piper marginatum Jacq. from Santarém-PA against Leishmania amazonensis 10.1016/j.exppara.2020.107847 2020
Nanoparticles Loaded with a New Thiourea Derivative: Development and In Vitro Evaluation Against Leishmania Amazonensis 10.2174/1567201817666200704132348 2020
Single-dose treatment for cutaneous leishmaniasis with an easily synthesized chalcone entrapped in polymeric microparticles 10.1017/s0031182020000712 2020
Encapsulation in lipid-core nanocapsules improves topical treatment with the potent antileishmanial compound CH8 10.1016/j.nano.2019.102121 2020
Vitamin D increases killing of intracellular Leishmania amazonensis in vitro independently of macrophage oxidative mechanisms 10.1017/s0031182020001791 2020
The role of TLR9 on Leishmania amazonensis infection and its influence on intranasal LaAg vaccine efficacy 10.1371/journal.pntd.0007146 2019
Pam3CSK4 adjuvant given intranasally boosts anti-Leishmania immunogenicity but not protective immune responses conferred by LaAg vaccine against visceral leishmaniasis 10.1016/j.micinf.2019.02.005 2019
Dietary Vitamin D3 Deficiency Increases Resistance to Leishmania (Leishmania) amazonensis Infection in Mice 10.3389/fcimb.2019.00088 2019
Nanoencapsulated retinoic acid as a safe tolerogenic adjuvant for intranasal vaccination against cutaneous leishmaniasis 10.1016/j.vaccine.2019.05.043 2019
Novel and safe single-dose treatment of cutaneous leishmaniasis with implantable amphotericin B-loaded microspheres. 10.1016/j.ijpddr.2019.06.001 2019
New Chalcone Compound as a Promising Antileishmanial Drug for an Old Neglected Disease: Biological Evaluation using Radiolabeled Biodistribution 10.1016/j.jgar.2017.11.012 2018
Optimization of Aqueous Extraction from Kalanchoe pinnata Leaves to Obtain the Highest Content of an Anti-inflammatory Flavonoid Using a Response Surface Model 10.1002/pca.2744 2018
Synthesis and leishmanicidal activity of eugenol derivatives bearing 1,2,3-triazole functionalities 10.1016/j.ejmech.2018.01.046 2018
Improved drug loading via spray drying of a chalcone implant for local treatment of cutaneous leishmaniasis 10.1080/03639045.2018.1461903 2018
The suppressive effects of Vochysia divergens aqueous leaf extract and its 5-methoxyflavone on murine macrophages and lymphocytes 10.1016/j.jep.2018.04.007 2018
Intralesional uridine-5--triphosphate (UTP) treatment induced resistance to Leishmania amazonensis infection by boosting Th1 immune responses and reactive oxygen species production 10.1007/s11302-018-9606-7 2018
Broad spectrum and safety of oral treatment with a promising nitrosylated chalcone in murine leishmaniasis 10.1128/AAC.00792-18 2018
Intranasal but not subcutaneous vaccination with LaAg allows rapid expansion of protective immunity against cutaneous leishmaniasis 10.1016/j.vaccine.2018.03.020 2018
Depot Subcutaneous Injection with Chalcone CH8-Loaded Poly(Lactic-Co-Glycolic Acid) Microspheres as a Single-Dose Treatment of Cutaneous Leishmaniasis 10.1128/AAC.01822-17 2018
Anti-parasitic effect of the diuretic and Na+-ATPAse inhibitor furosemide in cutaneous leishmaniasis 10.1017/S0031182017000695 2017
Synthesis and characterization of poly( N -vinylcaprolactam)-based spray-dried microparticles exhibiting temperature and pH-sensitive properties for controlled release of ketoprofen 10.1080/03639045.2017.1321660 2017
Lipid-core nanocapsules increase the oral efficacy of quercetin in cutaneous leishmaniasis 10.1017/s003118201700097x 2017
Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art 10.1017/S0031182017000993 2017
Leaves from the Tree Poincianella pluviosa as a Renewable Source of Antiplasmodial Compounds against Chloroquine-Resistant Plasmodium falciparum 10.21577/0103-5053.20170228 2017
The role of the P2X7 receptor in murine cutaneous leishmaniasis: aspects of inflammation and parasite control 10.1007/s11302-016-9544-1 2017
Fabrication of biocompatible and stimuli-responsive hybrid microgels with magnetic properties via aqueous precipitation polymerization 10.1016/j.matlet.2016.04.004 2016
Efficacy of intranasal LaAg vaccine against Leishmania amazonensis infection in partially resistant C57Bl/6 mice 10.1186/s13071-016-1822-9 2016
Intranasal vaccination with killed Leishmania amazonensis promastigotes antigen (LaAg) associated with CAF01 adjuvant induces partial protection in BALB/c mice challenged with Leishmania (infantum) chagasi - CORRIGENDUM 10.1017/s0031182015001584 2016
How Sorbitan Monostearate Can Increase Drug-Loading Capacity of Lipid-Core Polymeric Nanocapsules 10.1166/jnn.2015.9182 2015
Intranasal vaccination with leishmanial antigens protects golden hamster against Leishmania (Viannia) braziliensis infection. 10.1371/journal.pntd.0003439 2015
Serine Proteases and Vaccines against Leishmaniasis: A Dual Role 10.4172/2157-7560.1000264 2015
Identification of Serine Proteases from Leishmania braziliensis 10.1515/znc-2007-5-610 2014
Periodate-oxidized ATP Modulates Macrophage Functions During Infection with Leishmania amazonensis. 10.1002/cyto.a.22449 2014
Intranasal vaccination with extracellular serine proteases of Leishmania amazonensis confers protective immunity to BALB/c mice against infection 10.1186/1756-3305-7-448 2014
Chemical diversity and antileishmanial activity of crude extracts of Laurencia complex (Ceramiales, Rhodophyta) from Brazil 10.1016/j.bjp.2014.10.009 2014
Bone Marrow-Derived Mononuclear Cells Promote Improvement in Glomerular Function in Rats with Early Diabetic Nephropathy 10.1159/000354473 2013
Preparation and evaluation of chitosan-hydrophobic silica composite microspheres: Role of hydrophobic silica in modifying their properties 10.1016/j.powtec.2013.10.046 2013
Flowers from Kalanchoe pinnata are a Rich Source of T Cell-Suppressive Flavonoids 10.1177/1934578x1200700211 2012
The stepwise selection for ketoconazole resistance induces upregulation of C14-demethylase (CYP51) in Leishmania amazonensis 10.1590/S0074-02762012000300018 2012
Kalanchoe pinnata inhibits mast cell activation and prevents allergic airway disease. 10.1016/j.phymed.2011.06.030 2012
Peripheral expression of LACK-mRNA induced by intranasal vaccination with PCI-NEO-LACK defines the protection duration against murine visceral leishmaniasis 10.1017/S0031182012000868 2012
Therapeutic Potential of Biogenic Silver Nanoparticles in Murine Cutaneous Leishmaniasis 10.4028/www.scientific.net/jnanor.20.89 2012
Fluorescent-Labeled Poly(ε-caprolactone) Lipid-Core Nanocapsules: Synthesis, Physicochemical Properties and Macrophage Uptake 10.1166/jcsb.2012.1015 2012
Influence of cultivation conditions, season of collection and extraction method on the content of antileishmanial flavonoids from Kalanchoe pinnata 10.1016/j.jep.2010.09.020 2011
Infection with Leishmania amazonensis upregulates purinergic receptor expression and induces host-cell susceptibility to UTP-mediated apoptosis 10.1111/j.1462-5822.2011.01630.x 2011
MyD88-Dependent TLR1/2 Signals Educate Dendritic Cells with Gut-Specific Imprinting Properties 10.4049/jimmunol.1003740 2011
Effectiveness of the local or oral delivery of the novel naphthopterocarpanquinone LQB-118 against cutaneous leishmaniasis 10.1093/jac/dkr158 2011
Antileishmanial Sesquiterpenes from the Brazilian Red Alga 10.1055/s-0030-1250526 2011
Nanostructured Polymer and Lipid Carriers for Sunscreen. Biological Effects and Skin Permeation 10.1166/jnn.2011.3135 2011
Use of In Vivo and In Vitro Systems to Select Expressing Green Fluorescent Protein 10.3347/kjp.2011.49.4.357 2011
Intranasal immunization with LACK-DNA promotes protective immunity in hamsters challenged with Leishmania chagasi 10.1017/S0031182011001417 2011
Effectiveness of the immunomodulatory extract of Kalanchoe pinnata against murine visceral leishmaniasis 10.1017/S0031182009991405 2010
Leishmanicidal activity of Himatanthus sucuuba latex against Leishmania amazonensis 10.1016/j.parint.2010.01.002 2010
Serine proteases of Leishmania amazonensis as immunomodulatory and disease-aggravating components of the crude LaAg vaccine 10.1016/j.vaccine.2010.04.109 2010
Antitumoral, antileishmanial and antimalarial activity of pentacyclic 1,4-naphthoquinone derivatives 10.1590/S0103-50532009000100026 2009
Ivermectin-derived leishmanicidal compounds 10.1016/j.bmc.2008.12.003 2009
Semisolid Formulation Containing a Nanoencapsulated Sunscreen: Effectiveness, <I>In Vitro</I> Photostability and Immune Response 10.1166/jbn.2009.1028 2009
Altered sterol profile induced in Leishmania amazonensis by a natural dihydroxymethoxylated chalcone 10.1093/jac/dkn546 2009
Oral Metabolism and Efficacy of Kalanchoe pinnata Flavonoids in a Murine Model of Cutaneous Leishmaniasis 10.1055/s-0028-1088382 2009
Modulation of P2X7 purinergic receptor in macrophages by Leishmania amazonensis and its role in parasite elimination 10.1016/j.micinf.2009.05.001 2009
A nanotecnologia: Da saúde para além do determinismo tecnológico. 2008
Immunomodulatory pretreatment with Kalanchoe pinnata extract and its quercitrin flavonoid effectively protects mice against fatal anaphylactic shock 10.1016/j.intimp.2008.07.006 2008
The C-terminal extension of Leishmania pifanoi amastigote-specific cysteine proteinase Lpcys2: A putative function in macrophage infection 10.1016/j.molbiopara.2008.07.003 2008
Oligopeptidase B-2 from Leishmania amazonensis with an unusual C-terminal extension 10.2478/s11686-008-0026-7 2008
Protection against cutaneous leishmaniasis by intranasal vaccination with lipophosphoglycan. 10.1016/j.vaccine.2006.05.093 2007
High selective leishmanicidal activity of 3-hydroxy-2-methylene-3-(4-bromophenyl) propanenitrile and analogous compounds. 10.1016/j.ejmech.2006.07.013 2007
Intranasal delivery of naked DNA encoding the LACK antigen leads to protective immunity against visceral leishmaniasis in mice. 10.1016/j.vaccine.2006.11.060 2007
Interferon-gamma is required for the late but not early control of Leishmania amazonensis infection in C57Bl/6 mice 10.1590/S0074-02762007000100013 2007
Structure-Activity Relationship of Antileishmanials Neolignan Analogues . 10.1016/j.bmc.2007.08.016 2007
Oligopeptidase B from L. amazonensis: molecular cloning, gene expression analysis and molecular model 10.1007/s00436-007-0552-5 2007
Synthesis of chalcone analogues with increased antileishmanial activity 10.1016/j.bmc.2005.10.005 2006
Quercitrin: An Antileishmanial Flavonoid Glycoside from 10.1055/s-2005-873183 2006
Hyperbaric oxygen therapy reduces the size of Leishmania amazonensis-induced soft tissue lesions in mice 10.1016/j.actatropica.2006.03.001 2006
Role of residual Sb(III) in meglumine antimoniate cytotoxicity and MRP1-mediated resistance 10.1016/j.cbi.2006.01.008 2006
The antileishmanial activity assessment of unusual flavonoids from Kalanchoe pinnata 10.1016/j.phytochem.2006.06.027 2006
TGF-?-associated enhanced susceptibility to leishmaniasis following intramuscular vaccination of mice with antigens 10.1016/j.micinf.2005.04.016 2005
Antileishmanial activity of isolated triterpenoids from 10.1078/0944-7113-00381 2004
Oral delivery of meglumine antimoniate using beta-cyclodextrin for the treatment of leishmaniasis. 10.1128/AAC.48.1.100-103.2004 2004
The T-cell anergy induced by Leishmania amazonensis antigens is related with defective antigen presentation and apoptosis 10.1590/S0001-37652004000300006 2004
Intranasal Vaccination against Cutaneous Leishmaniasis with a Particulated Leishmanial Antigen or DNA Encoding LACK 10.1128/IAI.72.8.4521-4527.2004 2004
Eichl. (Menispermaceae): oral treatment decreases IgE levels and induces a Th1-skewed cytokine production in ovalbumin-sensitized mice 10.1016/j.jep.2004.06.037 2004
Interferon-gamma-inducing oral vaccination with Leishmania amazonensis antigens protects BALB/c and C57Bl/6 mice against cutaneous leishmaniasis. (IF = 2.822) 10.1016/S0264-410X(03)00427-4 2003
Pattern recognition and neural networks applied to structure-activity relationships of neolignans tested againstLeishmania amazonensis using quantum chemical and topological descriptors 10.1002/qua.10698 2003
Toxicological analysis and effectiveness of oralKalanchoe pinnata on a human case of cutaneous leishmaniasis 10.1002/ptr.1242 2003
Protein Prenylation in Trypanosomatids: A New Piggy-Back Medicinal Chemistry Target for the Development of Agents Against Tropical Diseases. 2001
Treatment of cutaneous leishmaniasis with Kalanchoe pinnata: experimental and clinical data. 2000
Pharmacological evaluation of Cecropia purpurascens.(IF = Qualis A) 2000
Isolation and Chemical Analysis of a Fatty Acid Fraction of Kalanchoe pinnata with a Potent Lymphocyte Suppressive Activity 10.1055/s-2000-11131 2000
Improvement of In Vitro and In Vivo Antileishmanial Activities of 2-,6--Dihydroxy-4--Methoxychalcone by Entrapment in Poly( -Lactide) Nanoparticles 10.1128/AAC.43.7.1776 1999
Cytokine profile in L. amazonensis-infected BALB/c mice after oral immunization with leishmanial antigens encapsulated in microspheres. 1999
Selective Effect of 2-,6--Dihydroxy-4--Methoxychalcone Isolated from on 10.1128/AAC.43.5.1234 1999
The anti-leishmanial effect of Kalanchoe is mediated by nitric oxide intermediates 10.1017/s0031182099004357 1999
Atividade Anti-Leishmania de Plumbago Scandens (Plumbaginaceae). 1998
Brazilian Medicinal Plants: A Rich Source Of Immunomodulatory Substances. 1997
A subset of gammadelta T-cell receptor-positive cells produce T-helper type-2 cytokines and regulate mouse skin graft rejection following portal venous pretransplant preimmunization 10.1046/j.1365-2567.1996.481554.x 1996
ROLE OF REACTIVE NITROGEN INTERMEDIATES IN THE REGULATION OF ALLOGENEIC SKIN GRAFT SURVIVAL IN MICE AFTER PORTAL VEIN PRETRANSPLANT TRANSFUSION 10.1097/00007890-199510150-00016 1995
Therapeutic effect of oral Kalanchoe pinnata leaf extract in murine leishmaniasis 10.1016/0001-706x(95)00128-2 1995
A Low-Cost And Efficient Procedure For Harvesting DNA Labeled Cells Using A Dot-Blot Apparatus. (IF = 2.286) 1994
Immunosuppressive effect of the aqueous extract ofKalanchoe pinnata in mice 10.1002/ptr.2650080704 1994
Inhibition of lymphocyte activation by extracts and fractions of Kalanchoe, Alternanthera, Paullinia and Mikania species 10.1016/s0944-7113(11)80065-6 1994
TH1 and TH2 T-cell subsets are differentially activated by macrophages and B cells in murine leishmaniasis 10.1128/iai.61.5.2266-2269.1993 1993
The direct effect of Kalanchoe leaf extract on Leishmania. 1992
Macrophages and B cells induce distinct Leishmania - reactive T cells. 1991
Leishmania -specific Th1 and Th2 T cells are activated by different antigen-presenting cells.. 1991
Trypanosoma brucei: Susceptibility to hydrogen peroxide and related products of activated macrophages 10.1016/0014-4894(88)90115-4 1988
Macrophage procoagulant activity in experimental African trypanosomiasis 10.1111/j.1365-3024.1987.tb00538.x 1987
T-lymphocyte requirement for the induction of mouse macrophage procoagulant activity by Trypanosoma brucei 10.1111/j.1365-3024.1987.tb00539.x 1987
Regulation of Procoagulant Factors in Mononuclear Phagocytes 10.1159/000215099 1984
Eventos:

(0.00% eventos com DOI)

Titulo DOI Ano
Estabelecimento de condições ideais de preparo de nanossistemas por nanoprecipitação visando transposição para microfluídica. 2021
'Low-Cost Microfluidic Device To Produce Biodegradable Polymeric Nanosystems For Drug Delivery' 2021
Particle design of antileishmanial transchalcone by super critical CO2 technology. 2016
Intralesional treatments with retinol or retinoic acid are effective against murine Leishmania amazonensis infection 2014
Sublingual vaccination with LaAg and LACK-DNA leads to increased expression of tolerogenic cytokines and protection against cutaneous leishmaniasis in BALB/c mice 2014
Encapsulation in lipid core nanocapsules (LNC) improves the topical efficacy of chalcone CH8 in cutaneous leishmaniasis 2014
Association with nanoencapsulated retinoic acid stimulates local regulatory T cell production and improves the efficacy of intranasal LaAg vaccine against murine Leishmania amazonensis infection. 2013
Adjuvant effect of retinoic acid in the intranasal LaAg vaccine effective against cutaneous leishmaniasis. 2012
The immunogenicity mechanism induced in cervical lymph nodes by the LACK DNA intranasal vaccine effective against murine leishmaniasis 2012
The adjuvant retinoic acid improves the antileishmanial LaAg intranasal vaccine efficacy and increases the CD4+ Foxp3+ population in the nasal mucosa. 2012
Dietary Vitamin A / retinoic acid modulates the efficacy of an antileishmanial oral vaccine. 2011
Mucosal Vaccines for Systemic Leishmaniasis. 2010
Safety assessment and use of glyceraldehyde-reticulated chitosan microparticles to improve the efficacy os the intranasal LACK-DNA vaccine against cutaneous leishmaniasis. 2009
Oral tratment of murine cutaneous leishmaniasis with a nitrated chalcone. 2009
Incorporation of a nitrated chalcone confers increased elasticity and skin permeability to non-peguilated liposomes with increased topical drug efficacy against cutaneous leishmaniasis. 2009
In Vitro Rheological Analysis to Evaluate Elasticity of Nanoparticles for Percutaneous Drug Delivery. 2009
"Vaccination by nasal route with extracelluler serine peptidases fraction of Leishmania amazonensis induced protection against Leishmania amazonensis protection against murine leishmaniasis" 2009
An intranasal DNA vaccine for visceral leishmaniasis that is systemically expressed and improved with microparticles 2008
Role of intestinal microbiota in the efficacy of an oral antileishmanial vaccine using germ-free mice. 2008
"Influence of retinol on the effectiveness of the oral LaAg vaccine against cutaneous leishmaniasis." 2008
Chitosan microparticles as potential carriers of an antileishmanial lack dna intranasal vaccine. 2007
. Pre-clinical studies of acute toxicity and allergenicity of glyceraldehyde- reticulated chitosan microparticles for intranasal drug and vaccine delivery. 2007
Safety testing in nanocosmetics: studies of allergenicity of poly- caprolactone nanocapsules with benzophenone-3 2007
Transgenic plants: an alternative for leishmaniasis vaccination? 2007
Antileishmanial LACK-DNA loaded in glyceraldehyde-crosslinked microparticles of chitosan for intranasal vaccination. 2007
The mucosa as a strategic route for antileishmanial vaccine delivery. 2007
Ausência de receptor P2X7 altera perfil inicial da infecção por Leishmania amazonensis e a migração de células para o sítio de Infecção in vivo. 2007
Macroalgas produtoras de moléculas ativas contra a Leishmaniose. 2007
ATP oxidado diminui a internalização de Leishmania amazonensis em macrófagos e atua como agente anti-leishmania em animais C57BL/6 P2X7R+/+ e P2X7 -/-. 2007
The pro-anaphylactic effect of TNF-alfa is independent of its TNFR1 receptor. 2007
The antianaphylactic efect of the partitioned aqueous extract of Kalanchoe pinnata and the flavonoid quercitrin. 2007
?Changes in lipid metabolism by a natural chalcone and its nitro-substituted synthetic analogue 2007
PAMAM dendrimers as controlled drug release systems to increase the activity of an antileishmanial chalcone. " 2007
P2 receptors: role in host defence against intracellular microorganisms. 2006
Tratamento oral com extrato aquoso de Kalanchoe pinnata protege camundongos BALB/ c contra a leishmaniose visceral. 2006
Efeito antianafilático do extrato aquoso de Kalanchoe pinnata em camundongos. 2006
Potencial Fitoterapêutico de Kalanchoe pinnata (Crassulaceae) no Tratamento da Leishmaniose. 2006
The purinergic receptor (P2X7R) plays a role in macrophage phagocytosis and may be involved in the establishment of L. amazonensis infection. 2006
Stimulation of growth concomitant with decreased infectivity of Leishmania amazonensis by ATP 2006
Intranasal immunization with a particulated Leishmania antigen protects BALB/c mice against visceral leishmaniasis. 2006
Edible vaccines: a promising alternative for leishmaniasis? 2006
Soluble serine proteases from L. amazonensis as disease-promoting components of the intramuscular LaAg vaccine. 2006
Chitosan microparticles as potential carriers of an antileishmanial LACK DNA intranasal vaccine. 2006
Chitosan microparticles as a delivery system for mucosal vaccines against leishmaniasis: pré-clinical studies of acute toxicity and allergenicity. 2006
New synthetic naphthoquinones that are highly inhibitory for Leishmania amazonensis. 2006
Antileishmanial chalcones with increased in vitro activity against African trypanososmes. 2006
Importância das serino proteases na vacinação contra a leishmaniose cutânea murina. 2006
Pre-clinical studies of acute toxicity and allergenicity of chitosan microspheres as a delivery system for antileishmanial mucosal vaccines. 2006
Intranasal delivery of naked DNA encoding the LACK antigen promotes systemic mRNA tissue expression and protects mice against visceral leishmaniasis. 2006
Intranasal vaccination with leishmanial antigens as an effective prophylactic measure against visceral leishmaniasis. 2006
Spray-dried chitosan microspheres as carriers of LACK-DNA intranasal vaccine against leishmaniasis. 2006
Pre-clinical studies of acute toxicity and allergenicity of chitosan microspheres as a delivery system for antileishmanial mucosal vaccines 2006
The Possible Involvement of P2X7 Receptor in the Establishment of Leishmania amazonensis infection. 2006
Dendrimers as carriers of antileishmanial drugs. 2005
The enhanced protectiveness of an intranasal leishmanial vaccine after encapsulation in neutral liposomes is associated with immunomodulation of mucosal and peripheral lymphoid tissues. 2005
Comparative study of acute toxicity and allergenicity of poly-hydroxybutyrate-valerate (PHB-HV) and poly- (lactide-co-glycolide) microparticles. 2005
The antileishmanial effect of ATP is associated with increased macrophage membrane permeability but not cell lysis. 2005
Effective mucosal vaccination against murine leishmaniasis. 2005
The disease-promoting effect of parenteral vaccination of mice with Leishmania amazonensis antigens is due to increased TGF-beta production. 2005
Antimony(v)-guanosine nanosystem: physicochemical characterization and evaluation in experimental model of leishmaniasis. 2005
PAMAM dendrimers as carriers of antileishmanial drugs. 2005
Comparative study of acute toxicity and allergenicity of poly-hydroxybutirate-valerate (PHB-HV) and poly-(lactide-co-glycolide) microparticles. 2005
Modulação da resposta ao cálcio intracelular induzida por nucleotídeos em macrófagos infectados com Leishmania amazonensis. 2005
Modulação da carga parasitária na infecção por Leishmania amazonensis mediada por nucleotídeos extracelulares. 2005
Suppresive effect of hyperbaric oxygen on the development of Leishmania amazonensis-induced lesions in susceptible mice. 2005
Immunological evaluation of attenuated leishmania amazonensis antigens. 2005
Parenteral vaccination with aprotinin agarose fractions of Leishmania amazonesis. 2005
Intranasal immunization with LACK-DNA promotes systemic tecidual mRNA expression and protects BALB/c mice against L. Chagasi infection. 2005
Therapeutic action of extracellular nucleotides on cutaneous leishmaniasis. 2005
The antileishmanial activity of the aqueous extract of a monoclonal Kalanchoe pinnata specimen. 2005
Efficacy of an intranasally administered vaccine containing fractions of L. amazonensis antigen against cutaneous leishmaniasis. 2005
Efficacy of an intranasally administered vaccine containing L. donovani antigens against cutaneous leishmaniasis. 2005
Effective mucosal vaccination against cutaneous leishmaniasis. 2005
Poly-Amidoamine (PAMAM) dendrimers as carriers of antileishmanial drugs. 2005
A role for P2X7receptor in leishmaniasis. 2005
Selective antileishmanial activity of a new synthetic naphthoquinone. 2005
Modulação da resposta ao calcio intracellular induzida por nucleotídeos em macrófagos infectados com Leishmania amazonensis. 2005
Inovação no tratamento de leishmaniose tegumentar murina: uso de dendrímeros PAMAM como carreadores de drogas. 2004
Identificação da quercitrina como principal flavonóide com atividade anti-leishmania no extrato de Kalanchoe pinnata. 2004
Papel do IFN-g no controle da infecção experimental com Leishmania amazonensis. 2004
Ativação do receptor P2X7 como estratégia terapêutica na leishmaniose e análise da susceptibilidade da célula infectada ao ATP. 2004
Modulation of anaphylactic shock in TNFR1 (p55) knock out mice. 2004
Use of particulated systems for nasal vaccination against cutaneous leishmaniasis. 2004
Efficacy of an intranasally administered vaccine containing L. donovani antigen against cutaneous leishmaniasis. 2004
Leishmania amazonensis and Leishmania braziliensis display differential capacity to induce T cell anergy which is associated with soluble molecules. 2004
Protective nasal vaccination against cutaneous leishmaniasis with hsp65 DNA-loaded microspheres. 2003
Cissampelos sympodialis Eichl. (Menispemaceae): oral treatment induces a Th1-skewed cytokine production in actively sensitized mice. 2003
TGF- beta-associated aggravation of leishmaniasis by a leishvacin-like vaccine in mice 2003
The mucosa as a strategic route for antileishmanial vaccine delivery. 2003
Effective intranasal vaccination against leishmaniasis using DNA-hsp65 encapsulated into TDM-loaded PLGA microspheres. 2003
Oral delivery of meglumine antimoniate using beta-cyclodextrin for the treatment of leishmaniasis. 2003
Enhanced protection against experimental cutaneous leishmaniasis using an intranasal vaccine encapsulated in liposomes. 2003
The long-lasting protection conferred by mucosal immunization against murine leishmaniasis 2003
Therapeutic action of ATP on cutaneous leishmaniasis. 2003
Oral delivery of meglumine antimoniate using beta-cyclodextrin for the treatment of leishmaniasis. 2003
A new synthetic chalcone with increased activity and selectivity against murine cutaneous leishmaniasis. 2003
TGF-beta and T cell apoptosis as immunosuppressive mechanism of Leishmania amazonensis antigen. 2003
Nasal vaccination with hsp65 DNA-loaded microspheres induces IFN-gamma and protects mice against leishmaniasis. 2003
Mucosal Vaccination with DNA encoding LACK parasite antigen protects mice against murine leishmaniasis. 2002
Anti-allergic property of Kalanchoe pinnata and associated down-modulation of cytokines in a murine model of anaphylactic shock. 2002
The role of TGF-b in the aggravation of infection of BALB/c mice vaccinated with Leishmania amazonensis lysate. 2002
The role of sterol biosynthesis inhibition on the activity of the natural chalcone dmc against Leishmania, Trypanosoma cruzi, Trypanosoma brucei and Candida spp. 2002
Estudo comparativo dos processos de cultivo e extração de Kalanchoe pinnata visando sua atividade inibidora de linfócitos. 2002
Oral immunization: A new strategy for protection against leishmaniasis. 2001
T suppressive components in L. amazonensis . 2001
Inhibition of sterol synthesis of L. amazonensis by a natural chalcone 2001
O extrato aquoso de Kalanchoe pinnata pode vir a ser uma nova substância na profilaxia de asma brônquica? 2001
Efeito do extrato aquoso de Kalanchoe pinnata na lesão pulmonar aguda induzida por lipopolissacarídeo de E. coli. 2001
Efeito do extrato de Kalanchoe pinnata na hiperreatividade brônquica. 2001
Mecanismos terapêuticos do Kalanchoe pinnata na leishmaniose: ativação da NO sintase e imunomodulação seletiva. 2001
Leishmanicidal activity of plants from Rio de Janeiro State 2001
Further insights into the use of GFP-transfected Leishmania for determination of parasite growth in vitro and in vivo. 2001
Mucosal immunization by oral or nasal routes protect mice against murine leishmaniasis. 2001
The role of TGF-b in the suppressive mechanisms of antigens from different leishmania species 2001
Particulate systems for targeting drugs and vaccines against leishmaniasis. 2001
Efeitos do extrato de Kalanchoe pinnata na mecânica respiratória de camundongos com hiperreatividade brônquica. 2000
Uso do extrato aquoso de Kalanchoe pinnata na proteção contra o choque anafilático em camundongos. 2000
Inibição da síntese de esteróis de Leishmania amazonensis pela 2' 6'-diidroxi-4'-metoxichalcona extraida de Piper aduncum. 2000
Treatment of cutaneous leishmaniasis with Kalanchoe pinnata: experimental and clinical data. 2000
Kalanchoe pinnata extract protects mice against anaphylatic shock induced by ovalbumin. 2000
The leishmanicidal mechanism of 2' 6´dihydroxy-4'-methoxychalcone involves the inhibition of parasite sterol synthesis. 2000
Antigen presenting cells are implicated in the anergy induced by Leishmania amazonensis antigens in BALB/c mice. 2000
Treatment of an Amazonian case of cutaneous leishmaniasis with Kalanchoe pinnata: toxicological and therapeutical data 2000
Oral versus subcutaneous immunization with leishmanial Ag encapsulated in microspheres - a new estrategy for protection in murine leishmaniasis 2000
The Involvement of P2Z/P2X7 receptors in inflammatory diseases. In: 1o International Workshop on Nucleotides and Their Receptors in the Immune System 2000
Enhanced Macrophage Permeabilization by ATP upon Leishmania Infection. 2000
Leishmanicidal activity and ultrastructural changes induced by sulphur synthetic neolignan analogues 1999
The improved antileishmanial activity of 2'-6'-dihydroxy-4'-methoxychalcone after encapsulation in poly (D,L-lactide) nanoparticles may be due to its intracellular targetting in macrophages. 1999
Popular medicinal plants used in Brazil as a source of immunosuppressive, antiviral, antiinflammatory and antiparasitary substances. 1999
Natural Products for the treatment of leishmaniasis 1999
Proposta estrutural para um flavonol 5-hidroxi-3'4'dimetoxi triglicosilado isolado da fração imunossupressora de Kalanchoe gastonis bonneri 1999
Leishmanial infection enhances ATP-induced permeabilization of macrophages 1999
Use of fluorescent leishmania for faster quantitation of parasite growth in vitro and in vivo 1999
Suppressed production of cytokines and T cell proliferation may be due to apoptosis induced by Leishmania amazonensis antigens. 1999
Searching T cell inhibitors in Leishmania amazonensis 1999
Oral immunization with leishmanial antigens delays the onset of infection with L. amazonensis 1999
Aqueous extract of Kalanchoe pinnata plant up-regulates TH1 cytokines in normal and Leishmania-infected mice 1999
Fração Apolar Isolada do Extrato Aquoso de Folhas de Kalanchoe Pinnata (Crassulaceae) Com Atividade Inibidora da Proliferação de Linfócitos. 1998
Síntese de Neolignanas Sulfuradas Com Atividade Antileishmania. 1998
Incorporation Into Poly (D, L -Lactide) Nanospheres Improves The Antileishmanial Action Of A Piper Aduncum Chalcone. 1998
Flavona e Flavonóis Isolados do Extrato Etanólico de Folhas de K. Pinnata. Fesbe. 1998
Modo de Ação e Potencialização da Atividade Leishmanicida de Uma Chalcona Isolada de Piper Aduncum. 1998
Ácidos Graxos da Planta Kalanchoe Pinnata São Responsáveis Pela Sua Atividade Imunossupressora. 1998
Fracionamento do Extrato da Planta Kalanchoe Pinnata Guiado Pela Atividade Imunossupressora e Anti-Leishmania. 1998
Atividade Leishmanicida e Alterações Ultraestruturais Induzidas Por Análogos Sulfurados de Neolignanas de Virola Surinamensis. 1998
Immunosupressive Activity Of Kalanchoe Pinnata In Leishmaniasis Is Related To Nitric Oxide Production And Apoptosis 1998
Leishmanicidal Activity And Ultrastructural Changes Induced By Sulphur Synthetic Neolignan Analogues. 1998
Oral Immunization With Leishmanial Antigens Encapsulated In Microspheres Preferentially Induce Ifn-* In L. Amazonensis -Infected Balb/C Mice. 1998
The T Cell Suppression Induced By Leishmania Amazonensis Antigens May Be Due To Apoptosis. 1998
A Chalcone Isolated From The Plant Piper Aduncum Is Selectively Toxic For Leishmania 1997
The Effectiveness Of Oral Kalanchoe Pinnata Treatment Is Related To Nitric Oxide Production. 1997
Efeito da 2', 6'-Diidroximetoxichalcona Encapsulada Em Nanoesferas Sobre A Leishmaniose Cutânea Experimental. 1997
Obtenção de Uma Fração Apolar do Extrato da Planta Kalanchoe Pinnata Rica Em Substâncias Seletivamente Tóxicas Para Leishmania. 1997
Enhancement Of A Plant-Derived Chalcone By Entrapment In Polymeric Nanospheres. 1997
Chemical Isolation Of An Apolar Antileishmanial And Lymphocyte- Suppressive Substances Present In The Plant Kalanchoe Pinnata. 1997
Oral immunization with leishmanial antigens induce a TH2-type phenotype in C57Bl/6 mice upon infection with Leishmania amazonensis 1997
A Chalcone isolated from the plant Piper aduncum is selectively toxic for Leishmania. 1997
Efeito Leishmanicida da 2', 6'- Diidroxi-4'-Metoxichalcona Isolada de Piper Aduncum. 1996
Reversão do Efeito Protetor da Planta Kalanchoe Na Leishmaniose Com Antagonista do Oxido Nitrico. 1996
Fitoquímica e Atividade Leishmanicida de Espécies de Piperaceae. 1996
Atividade Leishmanicida de Triterpenóides de Pourouma Guianensis. 1996
Activity Of A Pure Chalcone Isolated From Piper Aduncum (Piperaceae) On Leishmania Amazonensis. 1996
The Effectiveness Of Oral Kalanchoe Pinnata Treatment In Murine Leishmaniasis Is Reversed By A Nitric Oxide Inhibitor And Is Accompanied By Increased Il-2 Production. 1996
Lack Of Effect Of Extracellular Atp On The Induced Nitric Oxide Production And Leishmanicidal Activity Of Mouse Peritoneal Macrophages. 1996
Does Oral Immunization Induce Anergy In Cutaneous Leishmaniasis? 1996
Antileishmanial Effect Of A Pure Chalcone Isolated From Piper Aduncum (Piperaceae). 1996
Activity Of A Sulphur Synthetic Neolignan Analogue On Leishmania Amazonensis. 1996
Phytochemical Investigation Of Piper Aduncum. 1996
A flavonoi-rich fraction from the plant Kalanchoe pinnata may be responsible for its protective effect in leishmaniasis. 1996
A role for oligoclonally activated gamma-delta TCR+ IEL in adoptive transfer of inhibition of skin graft rejection in mice. 1995
Oligiclonal expansion of gamma delta TCR+ cells which adoptively transfer inhibition of skin graft rejection in mice after oral immunization. 1995
Plantas brasileiras com atividade leishmanicida: I-Moraceae. 1995
Produção de citocinas TH2 e regulação da rejeição de enxertos por células g/d TCR+ 1995
Kalanchoe flavonoids as possible immunosuppressive and antileishmanial agents. 1995
Modulação da resposta T por flavonoides e terpenos de Kalanchoe 1995
Effectiveness of oral treatment with Kalanchoe pinnata in murine cutaneous leishmaniasis. 1994
Antileishmanial effect of several plant extracts. 1994
Toxicological analysis of an antileishmanial plant extract 1994
Effect Of Kalanchoe Pinnata Leaf Extract On The Production Of Nitric Oxide By Leishmania-Infected Macrophages And Perforin By Cytolytic T Cells 1993
Kalanchoe Leaf Extract Impairs Presentation Of Leishmanial Antigens By Macrophages 1993
Immunological Changes Induced By A Protective Medicinal Plant In Leishmaniasis 1993
Use Of The Limiting Dilution Assay To Assess The Eficacy Of Kalanchoe And Glucantime Treatment In Murine Leishmaniasis 1993
Ativacao da Producao de Oxido Nitrico e Atividade Leishmanicida de Macrofagos Pelo Extrato de Kalanchoe Pinnata. 1993
Estimulacao da Producao de Producao de Perforina Por Linfocitos Citotoxicos Por K. Pinnata. 1993
Isolation of patuletin acetyl-rhamnosides from Kalanchoe brazieliensis 1993
Therapeutic Effect Of Kalanchoe Pinnata Leaf Extract In Experimental Cutaneous Leishmaniasis 1992
The Direct Effect Of Kalanchoe On Leishmania 1992
Treatment Of Experimental Cutaneous Leishmaniasis With Kalanchoe Leaf Extract 1992
Histopathologic Study Of Murine Leishmaniotic Lesions After Parenteral Treatment With Kalanchoe Leaf Extract 1992
The Effect Of Ultraviolet-B Radiation On The Immune Responses In Experimental Cutaneous Leishmaniasis 1992
Acao do Extrato Aquoso de Kalanchoe Pinnata Sobre O Parasita Leishmania. I. Estudo In Vivo 1992
Atividade Imunomoduladora de Plantas Medicinais Brasileiras 1992
Acao do Extrato Aquoso de Kalanchoe Pinnata Sobre O Parasita Leishmania. Ii. Estudos In Vitro 1992
Immunomodulatory Activity of Brazilian Medicinal Plants 1992
Acao Imunomoduladora da Planta Kalanchoe (Saiao) Em Camundongos. 1992
Leishmania-Specific Th1 And Th2 Helper T Cells Are Activated By Different Antigen Presenting Cells. 1991
Macrophages And B Cells Induce Distinct Leishmania-Reactive T Cells. 1991
Action Of Calcitonin And Gm-Csf On Experimental Cutaneous Leishmaniasis 1991
Expansion Of Different Leishmania-Specific T Cell Subsets By Macrophages And B Cells 1991
Mecanismos de Susceptibilidade e Resistencia Na Leishmaniose 1991
Macrophages and B lymphocytes as accessory cells in leishmaniasis 1990
Publicações:
Minha Rede: